Business Context and Reporting Period
This Form 8-K Current Report was filed by TPG RE Finance Trust, Inc. (TRTX) on June 7, 2021. The filing primarily addresses the entry into material definitive agreements regarding amendments to existing guaranty agreements and provides updates on loan origination activity in connection with a proposed public offering of Series C Cumulative Redeemable Preferred Stock.
Key Financial Metrics and Loan Activity
The filing does not provide consolidated revenue, profit, or cash flow statements. However, it details specific loan origination and repayment metrics since March 31, 2021:
- Loans Closed: Seven loans with an aggregate commitment of $548.5 million and initial funding of $429.5 million.
- Loan Repayment: Full repayment of one office loan with a commitment of $79.4 million and an unpaid principal balance of $78.8 million.
- Loan Pipeline: Signed term sheets for five potential loans representing $496.2 million in anticipated commitments.
- Portfolio Concentration (by commitment): Office 48% (39% life sciences), Multifamily 45%, Mixed-use 7%.
Material Changes: Covenant Amendments
On June 7, 2021, the Company's subsidiary, TPG RE Finance Trust Holdco, LLC, amended guaranty agreements with seven major lenders (Wells Fargo, Morgan Stanley, JPMorgan, Goldman Sachs, U.S. Bank, Barclays, and Bank of America). The amendments modified key financial covenants as follows:
| Covenant | Prior Requirement | New Requirement |
|---|---|---|
| Tangible Net Worth | Minimum $1.1 billion + 75% of subsequent equity issuances | Minimum $1.0 billion + 75% of subsequent equity issuances - 75% of redeemed/repurchased equity |
| Debt to Equity Ratio | Not to exceed 3.5 to 1.0 | Not to exceed 4.25 to 1.0 |
| Interest Coverage | Minimum 1.5 to 1.0 (EBITDA to interest expense) | Minimum 1.5 to 1.0 (EBITDA to interest expense) |
| Minimum Liquidity | Greater of $10 million or 5% of recourse indebtedness | Greater of $15 million or 5% of recourse indebtedness |
Outlook, Risks, and Contingencies
Outlook and Pipeline: The Company is underwriting five potential loans totaling $496.2 million. These are subject to due diligence, definitive documentation, and final approval by the Investment Review Committee; no assurance is given that they will close.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Specific risks cited include the performance of investments, the impact of the COVID-19 pandemic (geographic spread, severity, duration, and government actions), and the Company's ability to originate loans currently in the pipeline.
Key Facts for Investor Verification
- Verify the impact of the increased Debt to Equity covenant (3.5 to 4.25) on the Company's leverage capacity and future borrowing flexibility.
- Confirm the status of the $496.2 million loan pipeline and the likelihood of closing these deals given current market conditions.
- Review the details of the proposed Series C Cumulative Redeemable Preferred Stock offering mentioned in the context of recent loan activity.
- Assess the concentration risk in the office sector (48% of recent commitments), specifically the 39% exposure to life sciences.